Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15684093 | 0.89 | NR1H2 (0.41) | NR1H2PDE4BTACR1DDB1CRBN | |
| SCHEMBL20360129 | 0.87 | NR1H2 (0.42) | NR1H2PDE4BTACR1DDB1CRBN | |
| SCHEMBL20358500 | 0.87 | NR1H2 (0.42) | NR1H2PDE4BTACR1DDB1CRBN | |
| SCHEMBL20358501 | 0.87 | NR1H2 (0.42) | NR1H2PDE4BTACR1DDB1CRBN | |
| SCHEMBL1051376 | 0.84 | NR1H2 (0.53) | NR1H2PDE4BDDB1CRBNUSP2 | |
| SCHEMBL6065186 | 0.84 | NR1H2 (0.53) | NR1H2PDE4BDDB1CRBNUSP2 | |
| SCHEMBL1052921 | 0.84 | NR1H2 (0.53) | NR1H2PDE4BDDB1CRBNUSP2 | |
| SCHEMBL408327 | 0.83 | NR1H2 (0.40) | NR1H2PDE4BTACR1DDB1CRBN | |
| SCHEMBL15684240 | 0.83 | NR1H2 (0.40) | NR1H2PDE4BTACR1DDB1CRBN | |
| SCHEMBL278133 | 0.82 | NR1H2 (0.45) | NR1H2PDE4BDDB1CRBNUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137639-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160137639-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137639-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | CYP3A7, CYP2C19, CYP3A5 | NR1H2 2073/4885PDE4B 646/4885TACR1 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.